Cancer Research

BASEL, Switzerland, April 26 /PRNewswire/ -- - Roche Also Provides Comment on Results of "IDEAL" Trial Roche today announced that compelling new data from three studies indicate that chronic hepatitis C patients who received PEGASYS(R) (peginterferon alfa-2a) plus COPEGUS(R) (ribavirin) had a greater chance of being cured of their disease than those who received combination therapy with another pegylated interferon and ribavirin. Results from the studies were presented this week at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) in Milan, Italy. Ascione…

BASEL, Switzerland, April 26 /PRNewswire/ -- - R1626 Also Shows a High Barrier to the Development of Resistance Roche's investigational treatment for hepatitis C, R1626, has shown an impressive end-of-treatment response rate when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(R) (ribavirin). After 4 weeks of treatment with this triple combination, followed by 44 weeks of Pegasys and Copegus, levels of the hepatitis C virus (HCV) were undetectable in 84% of patients infected with genotype 1 virus. This was higher than in patients treated with Pegasys and Copegus…

BASEL, Switzerland, April 26 /PRNewswire/ -- - No Nucleoside/Nucleotide Analogue Treatments Have Shown Similar Results New data revealed today show that a significant number of patients with chronic hepatitis B virus infection who received PEGASYS(R) (peginterferon alfa-2a) treatment achieved clearance of a blood antigen known as hepatitis B s-antigen (HBsAg) (1). Clearance of this marker is associated with favourable clinical outcomes, and is as close to a cure as possible in this disease (1-4). HBsAg clearance shows that an individual's own immune system is able to control the infection.…

MILAN, April 26 /PRNewswire/ -- At today's sessions of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), experts reported advances in basic research that have important implications for the eventual treatment of people with chronic liver diseases. The goal of basic or "fundamental" biomedical science is to gain knowledge and understanding for its own sake, without reference to a particular practical problem. "Translational" science transforms basic knowledge into practical terms. "Applied" research, such as "clinical trials," takes the discoveries of…

INGELHEIM, Germany, April 25 /PRNewswire/ -- - For non-US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented Monotherapy treatment with the triple angiokinase inhibitor(1) BIBF 1120 (planned tradename VARGATEF(TM)) offers promising efficacy and is well tolerated in patients with advanced, relapsed non-small cell lung cancer (NSCLC), according to results from a phase II study in patients with lung cancer(2). Of particular note were results from a subset of 57 patients…

SAN DIEGO, April 24 /PRNewswire/ -- - HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008 - Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase 1 clinical trial of HspE7, its lead therapeutic candidate, in women with cervical intraepithelial neoplasia (CIN). Findings from the fourth cohort safety review demonstrated that HspE7 was safe and well tolerated with no serious adverse events being reported. (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/…

PLANEGG-MARTINSRIED, Germany, April 24 /PRNewswire/ -- The Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) announced today that the current Supervisory Board members Dr. Robert B. O'Connell and Dr. Brian Morgan intend to resign effectively at the end of the company's annual general shareholders' meeting taking place in Munich on 5 June 2008. At the upcoming general meeting, the Supervisory Board will propose as successors the nomination of Dr. Thomas Strüngmann and Helmut Jeggle, both representatives of Santo Holding (Germany) GmbH, the…

MILAN, Italy, April 23 /PRNewswire/ -- - Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy and New Insights into Mechanism of Action of Nitazoxanide Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in chronic hepatitis C virus (HCV) infection are being communicated in four presentations made at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), held in Milan, Italy this week. "These new studies confirm earlier data suggesting synergistic activity between…

COPENHAGEN, April 22 /PRNewswire/ -- - Consolidates the Global Rights for the Product - TopoTarget Successfully Buys Back Full Control of Belinostat, Consolidating the Global Rights for the Product - TopoTarget Acquires US & RoW Rights From CuraGen Corporation - Deal Covers a Payment of USD 26 million (DKK 122.8 million), a Total of 5 Million TopoTarget Shares and a Commercial Milestone Payment - Webcast Conference Call to be Held 2pm CET TopoTarget A/S (OMX: TOPO) today announced that the company has successfully gained full control of belinostat so that global rights are now wholly…

A new study has found that between 1983 and 1999, the death rate in women increased in a large number of the worst-off counties in the US, primarily because of chronic diseases related to smoking, high blood pressure, and obesity. As a result of this stagnation or decline in the health of the worst-off segment of the population, inequality in life expectancy across different counties of the US worsened. Majid Ezzati of Harvard University and colleagues analyzed death rates in all counties of the US states plus the District of Columbia over four decades, from 1961 to 1999. They obtained data…